主要研究目的：研究空腹/餐后状态下口服受试制剂精氨酸培哚普利片（江西施美药业股份有限公司生产）与参比制剂精氨酸培哚普利片（COVERSYL®，Les Laboratoires Servier生产）在中国健康成年受试者体内的药代动力学特征，评价空腹/餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂精氨酸培哚普利片和参比制剂精氨酸培哚普利片（COVERSYL®）在中国健康成年受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation Perindopril Arginine Tablets (produced by Jiangxi Shimei Pharmaceutical Co., Ltd.) and the reference preparation Perindopril Arginine Tablets (COVERSYL®, produced by Les Laboratoires Servier) in healthy Chinese adult subjects in the fasting/fed state, and to evaluate the bioequivalence of the two preparations in the fasting/fed state. Secondary purpose of the study is to evaluate the safety of the test preparation Perindopril Arginine Tablets and the reference preparation Perindopril Arginine Tablets (COVERSYL®) in healthy Chinese adult subjects.

Start Date26 Feb 2024

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

CTR20233406

/ CompletedNot Applicable

精氨酸培哚普利片人体生物等效性研究

[Translation] Study on the bioequivalence of arginine perindopril tablets in healthy volunteers

本试验旨在研究单次空腹和餐后口服石家庄四药有限公司研制、生产的精氨酸培哚普利片（10mg）的药代动力学特征；以Les Laboratoires Servier持证的精氨酸培哚普利片（Coversyl，10mg）为参比制剂，比较两制剂中药动学参数，评价两制剂的人体生物等效性，并观察两制剂在健康受试者中的安全性。

[Translation]

This study aims to study the pharmacokinetic characteristics of a single fasting and postprandial oral administration of arginine perindopril tablets (10 mg) developed and produced by Shijiazhuang Siyao Co., Ltd.; using arginine perindopril tablets (Coversyl, 10 mg) certified by Les Laboratoires Servier as the reference preparation, compare the pharmacokinetic parameters of the two preparations, evaluate the human bioequivalence of the two preparations, and observe the safety of the two preparations in healthy subjects.

Start Date23 Nov 2023

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

CTR20230504

/ CompletedNot Applicable

一项单中心、随机、开放、单次给药、两制剂、两周期交叉设计研究评价杭州仟源保灵药业有限公司的精氨酸培哚普利片与Les Laboratoires Servier的精氨酸培哚普利片在健康受试者中的空腹和餐后状态下的生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, two-dose, two-period crossover design study to evaluate the bioequivalence of arginine perindopril tablets from Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. and arginine perindopril tablets from Les Laboratoires Servier in healthy subjects under fasting and fed conditions

主要研究目的：评价杭州仟源保灵药业有限公司的精氨酸培哚普利片与Les Laboratoires Servier的精氨酸培哚普利片空腹和餐后单次口服给药后在健康人群中的生物等效性。次要研究目的：评价受试制剂和参比制剂在健康人群中的安全性。

[Translation]

Primary study objective: To evaluate the bioequivalence of the arginine perindopril tablets of Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. and the arginine perindopril tablets of Les Laboratoires Servier in healthy subjects after single oral administration on an empty stomach and after meals. Secondary study objective: To evaluate the safety of the test preparation and the reference preparation in healthy subjects.

Start Date13 Feb 2023

Sponsor / Collaborator

Hangzhou QIANYUAN Pollen Pharmaceutical Co., Ltd.

100 Clinical Results associated with Perindopril Arginine

100 Translational Medicine associated with Perindopril Arginine

100 Patents (Medical) associated with Perindopril Arginine

2,117

Literatures (Medical) associated with Perindopril Arginine

01 Apr 2025·ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY

Five-month real-ambient PM2.5 exposure impairs learning in Brown Norway rats: Insights from multi omics-based analysis

Article

Author: Zhao, Wenjie ; Xu, Yanfeng ; Xiong, Yi ; Sun, Xiuping ; Han, Yunlin ; Song, Chenchen ; Zhou, Li ; Zhao, Lianlian ; Shan, Shan ; Guo, Jianguo ; Guo, Jindan ; Yang, Hu ; Zhang, Ling ; Zhang, Boxiang

PM_2.5, recognized as a potential pathogenic factor for nervous system diseases, remains an area with many unknowns, particularly regarding its effects on human health. After five-month real-ambient PM_2.5 exposure, we observed no significant pathological damage to the lung, liver, spleen, or kidney tissues. However, PM_2.5 exposure led to neuronal degeneration in the hippocampal CA1 region of Brown Norway (BN) rats. The level of IL-6, IL-13, IL-1β, IL-12, IL-4, GRO/KC, MIP-1α, CM-CSF significantly increased in lung lavage fluid (P < 0.05 for all). Notably, we detected a slight impairment in spatial learning ability, as evidenced by the Barnes maze training outcomes. There were no significant changes in the bacterial community in lung lavage fluid (P = 0.621), but the bacterial community in the gut significantly changed (P < 0.001), with more species identified (P < 0.05). The metabolomic analysis revealed 147 and 149 significantly changed metabolites in the pulmonary system and serum, respectively (P < 0.05). PM_2.5 exposure caused a decrease in Nervonic acid (NA) in both the lung and serum, which likely contributed to spatial learning impairment (P < 0.01). The correlation between lung metabolites, gut bacterial species, and serum metabolites indicated that PM_2.5 exposure likely impaired spatial learning through the lung-gut-brain axis pathway. Lung and serum metabolic disorders and intestinal microbial imbalance occurred in BN rats post-five-month real-ambient PM_2.5 exposure. There were two potential ways that PM_2.5 exposure caused the decline of spatial learning ability in wild-type BN rats: (1) PM_2.5 exposure led to a significant decrease of neuroprotective Nervonic acid in lung and serum metabolites. (2) PM_2.5 exposure likely led to reduced spatial learning ability through the lung-gut-brain axis.

01 Apr 2025·JOURNAL OF PHARMACEUTICAL SCIENCES

Optimization of HPLC method for determination of Abraham solvation parameters of pharmaceuticals

Article

Author: Knašienė, Birutė ; Sadaunykas, Audrius ; Sazonovas, Andrius ; Naujalis, Evaldas ; Lanevskij, Kiril ; Balčiūnas, Simonas

Abraham solvation equation (Absolv) is a popular and well-established approach for modeling solute partitioning between phases of different polarity, which finds its applications in both organic chemistry and biomedical fields. Parameters constituting this equation are good quantitative descriptors of solute hydrogen bonding potential that are useful for QSAR modeling of more complex chemical and biological phenomena. Numerous studies dealing with fast determination of Abraham descriptors using HPLC can be found in the literature, but these mostly focus on small un-ionizable industrial and environmental chemicals, whereas experimental data for pharmaceutical molecules are clearly lacking. In the current study we build upon a previously published chromatographic approach, aiming to adapt the method to ionizable drug-like compounds, and optimize it by reducing the number of required HPLC columns. The analysis involves determination of the overall H-bond acidity (A), H-bond basicity (B) and polarity/polarizability (S) descriptors for 62 pharmaceutical molecules with previously unpublished parameter values.

01 Mar 2025·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Psoriasis after exposure to angiotensin converting enzyme inhibitors: Clinical features of a signal from the WHO pharmacovigilance database

Article

Author: Trenque, Thierry ; Azzouz, Brahim ; Viguier, Manuelle

A potential link between angiotensin-converting enzyme inhibitors (ACEIs) and psoriasis was investigated using the WHO pharmacovigilance database, VigiBase.Analyzing 467 psoriasis cases, plaque psoriasis was most common (84.8%), with severe forms of psoriasis also identified.Lisinopril and ramipril were the most frequently implicated ACEIs.The median onset time was 60 days, and 61% of cases improved after drug discontinuation.Disproportionality anal. confirmed strong safety signals for ACEI-psoriasis associationsThese findings highlight the need for prescriber awareness and consideration of alternative treatments for affected patients.

News (Medical) associated with Perindopril Arginine

05 Sep 2023

·www.biospace.com

Pharmascience Canada launches a new generic drug to treat hypertension

[05-September-2023] MONTREAL, Sept. 5, 2023 /CNW/ - pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine / indapamide) is used in adults for the initial treatment of mild to moderate essential hypertension (high blood pressure). pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine/ indapamide) are a combination of perindopril erbumine, an angiotensin converting enzyme (ACE) inhibitor, and indapamide, a chlorosulphamoyl diuretic. These two active ingredients act synergistically to lower blood pressure in hypertensive patients of all ages. pms-PERINDOPRIL-INDAPAMIDE comes in the following dosage forms: Tablets of 2 mg perindopril erbumine/ 0.625 mg indapamide. Tablets of 4 mg perindopril erbumine/ 1.25 mg indapamide. Tablets of 8 mg perindopril erbumine/ 2.5 mg indapamide. pms-PERINDOPRIL-INDAPAMIDE is a generic equivalent to Coversyl® Plus, Coversyl® Plus LD and Coversyl® Plus HD and has the same safety and efficacy as Coversyl®. pms-PERINDOPRIL-INDAPAMIDE tablets are offered at a lower price than brand-name products. "The Pharmascience team is happy to bring to market pms-Perindopril-Indapamide used for the initial treatment of high blood pressure. The availability of pms-Perindopril-Indapamide gives every Canadian an affordable and important treatment option! At Pharmascience, we take tremendous pride in our locally produced medicines and will continue to focus on growing our portfolio with quality medications needed for all Canadians!" - mentioned Mike Dutton, Vice President, and General Manager of Pharmascience Canada. ABOUT PHARMASCIENCE INC. Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada. Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2023, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada's Top Employers for Young People as part of Canada's Top 100 Employers. Pharmascience is now certified as a Great Place to Work for a second year in a row. For product information, please contact Pharmascience's Medical Information Department at 1-888-550-6060. Coversyl® Plus, Coversyl® Plus LD and Coversyl® Plus HD are registered trademark owned by Servier Canada Inc. SOURCE Pharmascience Inc.

Drug Approval

100 Deals associated with Perindopril Arginine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Perindopril Arginine	C09AA04	DB00790

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	China	Les Laboratoires Servier SAS	17 Oct 2014
Coronary Disease	Australia	SERVIER LABORATORIES (AUST.) PTY. LTD.	08 Jun 2005
Heart Failure	Australia	SERVIER LABORATORIES (AUST.) PTY. LTD.	08 Jun 2005
Hypertension	Australia	SERVIER LABORATORIES (AUST.) PTY. LTD.	08 Jun 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01118520 (AARDVARK, CTgov)	Phase 2	Mydriasis \| Aortic Aneurysm, Abdominal	224	perindopril arginine (Perindopril)	cxxmwtsebn(aoqnqnohes) = idbwwqnojx ehllxshqie (rxdzzgsmux, 0.02) View more	-	26 Jan 2021
				amlodipine 5mgs (Amlodipine)	cxxmwtsebn(aoqnqnohes) = wvlfomipns ehllxshqie (rxdzzgsmux, 0.02) View more
NCT01669434 (CTgov)	Phase 4	Hypotension	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	cwutvnxwik = tqwucchekf gguedjyokc (gabtmiqmik, cyqzkvmbrb - otjtjyikbs) View more	-	11 Dec 2017
				ACEI continuation (ACEI Continuation)	cwutvnxwik = cntirevdnq gguedjyokc (gabtmiqmik, cuswtqhsqb - wjpmgzpkif) View more
PP.28.100 (ESH2010)	Not Applicable	Hypertension	2,200	Perindopril 5 mg	dlarirgguu(bfxtycpkao) = 2.5% hpodjpapxm (azixcvthpe )	Positive	01 Jun 2010
				Perindopril 10 mg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis